Pancreatic duct stent placement prevents post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction but normal manometry results

Gastrointest Endosc. 2008 Feb;67(2):255-61. doi: 10.1016/j.gie.2007.06.022. Epub 2007 Oct 29.

Abstract

Background: Placement of a pancreatic duct (PD) stent reduces post-ERCP pancreatitis rates in high-risk patients. Patients with suspected sphincter of Oddi dysfunction (SOD) who are found to have normal manometry results (SOM) are also at high risk for this complication.

Objective: Our purpose was to determine whether PD stent placement reduces pancreatitis rates in this patient population.

Design: Non-randomized, retrospective study.

Setting: Large, tertiary referral center.

Patients: From January 1999 to December 2005, patients who underwent ERCP with normal SOM were identified from our ERCP database. Incidence of patient/procedure risk factors for post-ERCP pancreatitis, trainee participation, and prior sphincter therapy were evaluated.

Interventions: PD stent placement.

Main outcome measurement: Pancreatitis rates.

Results: A total of 403 patients were available for analysis: 169 had a PD stent placed (group 1) and 234 did not (group 2). Overall, pancreatitis rates were 2.4% in group 1 and 9.0% in group 2 (P= .006, odds ratio 4.1, 95% CI 1.4-12.0). Other than increased PD opacification in group 1 (P< .001), the incidence of risk factors for pancreatitis, trainee participation, or prior sphincter therapy was similar between the 2 groups. In patients with an intact papilla, stent placement reduced the rate of pancreatitis from 11.5% to 2.7% (P= .012). In patients with prior sphincter therapy, no benefit was seen from stent placement, although there was a trend to decreased pancreatitis rates in stented patients with prior pancreatobiliary sphincterotomy.

Limitations: Nonrandomized, retrospective design.

Conclusion: Temporary PD stent placement reduces pancreatitis rates in patients with suspected SOD but normal SOM and an intact papilla. Their routine use is recommended when evaluating this difficult, high-risk patient population.

MeSH terms

  • Adult
  • Cholangiopancreatography, Endoscopic Retrograde / adverse effects*
  • Female
  • Humans
  • Logistic Models
  • Male
  • Manometry
  • Pancreatic Ducts*
  • Pancreatitis / etiology
  • Pancreatitis / prevention & control*
  • Retrospective Studies
  • Risk Factors
  • Sphincter of Oddi Dysfunction / complications*
  • Stents*
  • Time Factors